Clinical trials: Prostatic Disease
Overactive Bladder, Benign Prostatic Hyperplasia
Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)
OAB occurs in approximately 50% to 75% of men with BPO and up to 38% of men with BPO continue to suffer from OAB after relief the obstruction.Symptoms of OAB are more bothersome than the voiding complaints of slow stream and…
- Trial name
- NCT00922506
- Testing
- doxazosin plus tolterodine SR
- Where
- South Korea
- Volunteers
- 83 people
- Sponsor
- Samsung Medical Center
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors
The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed…
- Conditions
- Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma)
- Trial name
- ACCESS-PC (NCT06834204)
- Testing
- PC2: Primary Care Connect
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Trial of eRapa in Prostate Cancer Patients
This study is to determine the safety, pharmacokinetics/pharmacodynamics, and immunologic impact of encapsulated rapamycin in patients with low risk prostate cancer under active surveillance.
- Trial name
- NCT03618355
- Testing
- eRapa (encapsulated rapamycin)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rapamycin Holdings, Inc. dba Emtora Biosciences
Prostate Cancer
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as goserelin, may stop the adrenal glands from making androgens.
- Trial name
- NCT00104715
- Testing
- antiandrogen therapy, docetaxel, goserelin acetate
- Where
- 41 sites in France
- Volunteers
- 385 people
- Sponsor
- UNICANCER
Prostate Cancer
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body.
- Trial name
- DAROL (NCT04122976)
- Testing
- Darolutamide(Nubeqa, BAY1841788)
- Where
- 40 sites in United States, Argentina and 15 more
- Volunteers
- 805 people
- Sponsor
- Bayer
Prostate Cancer
18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer
To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.
- Trial name
- PICture (NCT04487847)
- Testing
- 18F-PSMA-1007 PET/CT
- Where
- Netherlands
- Volunteers
- 75 people
- Sponsor
- Radboud University Medical Center
Benign Prostatic Hyperplasia
Comparison of TUSP Versus TURP for Treatment of Benign Prostatic Hyperplasia in a Small Prostate Volume
Comparison of transurethral split of the prostate versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia in a small prostate volume: A prospective controlled study
- Trial name
- NCT04912349
- Testing
- TUSP, TURP
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Benign Prostatic Hyperplasia, Enlarged Prostate
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.
- Trial name
- NCT00435448
- Testing
- Lonidamine
- Where
- 58 sites in Germany, Hungary and 2 more
- Volunteers
- 480 people
- Sponsor
- Threshold Pharmaceuticals
Prostate Cancer, Prostate Cancer Metastatic
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
The goal of this research is to examine the ability of Gallium-68 (68Ga) Prostate-Specific Membrane Antigen-11 (PSMA-11) positron emission tomography/computed tomography (PET/CT) to detect sites of recurrent prostate cancer in…
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
- Trial name
- NCT04483414
- Testing
- 68Ga PSMA-11 injection, Positron Emission Tomography/Computed Tomography
- Where
- United States
- Sponsor
- Dana Mathews
Prostate Cancer
Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer
The purpose of this study is to evaluate the incidence of urinary and gastrointestinal acute and late side effects in patients treated with stereotactic body radiotherapy (SBRT) to the prostate.
- Trial name
- SMART (NCT00941915)
- Testing
- SBRT Prostate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Prostate Cancer
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination.
- Trial name
- NCT03934840
- Testing
- Cabazitaxel, Carboplatin, Abiraterone
- Where
- 8 sites in United States
- Volunteers
- 61 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostate Cancer
Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)
This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer.
- Trial name
- ProGen (NCT03328091)
- Testing
- Traditional pre-test genetic counseling, Pre-test video education
- Where
- 3 sites in United States
- Volunteers
- 662 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms
Exisulind Prior to Radical Prostatectomy
This trial will compare no treatment to exisulind therapy. Patients enrolled on the treatment arm will begin treatment 4 weeks prior to the scheduled date of surgical removal of the prostate and will take 375 mg by mouth daily…
- Trial name
- NCT00166478
- Testing
- Exisulind Therapy
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Mayo Clinic
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score.
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04513717
- Testing
- Apalutamide, Bicalutamide, Biospecimen Collection
- Where
- 602 sites in United States, Canada
- Volunteers
- 2,753 people
- Sponsor
- NRG Oncology
Diagnoses Disease
Micro-Ultrasound/Magnetic Resonance Imaging 001
Micro-ultrasound is a novel real-time imaging modality which maintains the clinical workflow of conventional ultrasound-guided prostate biopsy, while potentially maintaining a similar ability to detect clinically significant…
- Trial name
- NCT03938376
- Testing
- Micro-Ultrasound guided biopsy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer, Urological Cancer
Evaluation of the PI-RADS v2.1 Score Using Multiple Readers
The interpretation of prostate multiparametric MRI (mpMRI) is difficult and requires expertise. As a result, it suffers from substantial inter-reader variability.
- Trial name
- MULTI (NCT04299997)
- Testing
- Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients
The objective of this study is to evaluate the feasibility of two different chemotherapy protocols with adjusted doses for patients aged 75 and over who often have medical problems other than prostate cancer.
- Trial name
- GERICO10 (NCT01254513)
- Testing
- Docetaxel every 3 weeks + Prednisone, Docetaxel weekly+ Prednisone
- Where
- 31 sites in France
- Volunteers
- 66 people
- Sponsor
- UNICANCER
Prostate Carcinoma
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion…
- Trial name
- ECLIPSE (NCT07185165)
- Testing
- Computed Tomography, Fluorine F 18 Flotufolastat, Positron Emission Tomography
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostatic Neoplasms
Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)
The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.
- Trial name
- PROPELLER (NCT04839367)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 3 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT).
- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT07339267
- Testing
- ASP5541, Prednisone
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Global Development, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.